Protagenic Therapeutics I... (PTIXW)
0.01
0.00 (53.85%)
At close: Jan 14, 2025, 9:00 PM
Company Description
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
The company was founded in 2016 and is based in New York, New York.
Protagenic Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 149 Fifth Avenue New York, New York United States | |
| Website | http://www.protagenic.com |
Stock Details
| Ticker Symbol | PTIXW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N111 |
| ISIN Number | US74365N1110 |
| Employer ID | 06-1390025 |
| SIC Code | 7389 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer & Secretary |
| Dr. Andrew Slee Ph.D. | Chief Operating Officer |
| Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 424B5 | Filing |
| Jan 07, 2025 | S-3/A | [Amend] Filing |
| Jan 06, 2025 | DEFA14A | Filing |
| Jan 03, 2025 | DEF 14A | Filing |
| Dec 27, 2024 | 424B3 | Filing |
| Dec 20, 2024 | S-1 | Filing |
| Dec 19, 2024 | PRE 14A | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |